Biography:
Johnna D. Wesley, MPH, Ph.D., is the Scientific Vice President of Type 1 Diabetes (T1D) and Immunology at Novo Nordisk. Dr. Wesley and her colleagues across the globe work on finding curative or preventative therapies for T1D and to understand the role of immune dysfunction in cardiometabolic diseases. This work involves characterization of the disease pathology in humans; translational biomarkers for predicting drug responses and disease outcomes; and novel in vitro platform development for screening compounds and mechanistic studies.
Title : Challenges in drug development for T1D: Model systems and biomarkers